MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
MiNK Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 17, 2026. A total of 3,277,906 shares of common stock were present in person or by proxy, representing 65.79% of shares outstanding and establishing a quorum.
Stockholders elected Garo Armen, Barbara Ryan and John Holcomb as Class II directors for three-year terms ending at the 2029 annual meeting. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented: 3,277,906 shares
Participation rate: 65.79%
Votes for Garo Armen: 2,363,360
+5 more
8 metrics
Shares represented
3,277,906 shares
Present or by proxy at June 17, 2026 annual meeting
Participation rate
65.79%
Shares outstanding and eligible to vote at annual meeting
Votes for Garo Armen
2,363,360
For votes in Class II director election
Votes for Barbara Ryan
2,362,760
For votes in Class II director election
Votes for John Holcomb
2,381,491
For votes in Class II director election
Auditor ratification for votes
3,249,124
Votes for KPMG LLP as auditor for fiscal 2026
Auditor ratification against votes
26,560
Votes against KPMG LLP ratification
Auditor ratification abstain votes
2,222
Abstentions on KPMG LLP ratification
Key Terms
Annual Meeting of Stockholders, quorum, Class II Directors, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders financial
"The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 17, 2026."
quorum financial
"representing 65.79% of the shares outstanding and eligible to vote and constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Class II Directors financial
"to elect Garo Armen, Barbara Ryan and John Holcomb as Class II Directors, each for a term of three years"
independent registered public accounting firm financial
"to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"Garo Armen | 2,363,360 | 0 | 32,898 | 881,648"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
What did MiNK Therapeutics (INKT) stockholders vote on at the 2026 annual meeting?
Stockholders voted to elect three Class II directors and to ratify KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Both the director elections and auditor ratification received sufficient support to be approved.
Which directors were elected at MiNK Therapeutics (INKT) 2026 annual meeting and for how long?
Stockholders elected Garo Armen, Barbara Ryan and John Holcomb as Class II directors. Each will serve a three-year term expiring at the 2029 Annual Meeting of Stockholders, continuing their roles on the company’s board of directors through that period.
What were the vote results for MiNK Therapeutics (INKT) director elections?
For the Class II directors, votes for ranged from 2,362,760 to 2,381,491, with zero votes against for each nominee. Withheld votes ranged from 14,767 to 33,498, and there were 881,648 broker non-votes recorded for each director nominee.
Did MiNK Therapeutics (INKT) stockholders ratify KPMG LLP as auditor for 2026?
Yes. Stockholders approved the ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 3,249,124 votes for, 26,560 votes against, and 2,222 votes abstaining, and no broker non-votes recorded.
When was MiNK Therapeutics’ (INKT) 2026 annual meeting held and who signed the report?
The Annual Meeting of Stockholders was held on June 17, 2026. The related report was signed on behalf of MiNK Therapeutics by President and CEO Jennifer S. Buell, Ph.D., dated June 23, 2026, confirming the voting results disclosed.